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Abstract
Background: In patients with high risk stage II and stage III colon cancer (CC), curative surgery followed by adjuvant
FOLFOX-4 chemotherapy has become the standard of care. However, for 20 to 30 % of these patients, the
current curative treatment strategy of surgical excision followed by adjuvant chemotherapy fails either to clear
locoregional spread or to eradicate distant micrometastases, leading to disease recurrence. Preoperative chemotherapy is
an attractive concept for these CCs and has the potential to impact upon both of these causes of failure. Optimum
systemic therapy at the earliest possible opportunity may be more effective at eradicating distant metastases than the
same treatment given after the delay and immunological stress of surgery. Added to this, shrinking the primary tumor
before surgery may reduce the risk of incomplete surgical excision, and the risk of tumor cell shedding during surgery.
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Methods/Design: PRODIGE 22 - ECKINOXE is a multicenter randomized phase II trial designed to evaluate efficacy
and feasibility of two chemotherapy regimens (FOLFOX-4 alone and FOLFOX-4 + Cetuximab) in a peri-operative
strategy in patients with bulky CCs. Patients with CC deemed as high risk T3, T4 and/or N2 on initial abdominopelvic CT
scan are randomized to either colectomy and adjuvant chemotherapy (control arm), or 4 cycles of neoadjuvant
chemotherapy with FOLFOX-4 (for RAS mutated patients). In RAS wild-type patients a third arm testing FOLFOX+
cetuximab has been added prior to colectomy. Patients in the neoadjuvant chemotherapy arms will receive
postoperative treatment for 4 months (8 cycles) to complete their therapeutic schedule. The primary endpoint
of the study is the histological Tumor Regression Grade (TRG) as defined by Ryan. The secondary endpoints are:
treatment strategy safety (toxicity, primary tumor related complications under chemotherapy, peri-operative morbidity),
disease-free and recurrence free survivals at 3 years, quality of life, carcinologic quality and completeness of the surgery,
initial radiological staging and radiological response to neoadjuvant chemotherapy, and the correlation between
histopathological and radiological response. Taking into account a 50 % prevalence of CC without RAS mutation, accrual
of 165 patients is needed for this Phase II trial.
Trial Registration: NCT01675999 (ClinicalTrials.gov)
Keywords: Colon cancer, Locally advanced disease, Neoadjuvant chemotherapy, FOLFOX, Cetuximab, Randomized
phase II trial
Background
With about 1 million new cases in developed countries
annually and 500 000 annual deaths, colon cancer (CC) is
the second leading cause of cancer death in Western
countries and a significant public health issue [1]. Curative
treatment of CC, possible in nearly 80 % of cases, is based
on carcinologic surgical resection. For stage III CC (any
T/N1-2/M0), adjuvant FOLFOX-4 chemotherapy for
6 months is the standard of care. In the MOSAIC trial [2]
that compared adjuvant LV5FU2 with FOLFOX-4 in 2246
stage II and III CC patients, there was a significant in-
crease in disease-free survival at 3 years in the FOLFOX-4
group (78.2 % vs. 72.9 %, for all patients combined; 72.2 %
vs. 65.3 % for the stage III subgroup). The 5 % difference
in events at 3 years (26.1 % vs. 21.1 %) resulted in a hazard
ratio (HR) of 0.77 corresponding to a 23 % risk reduction
for patients receiving oxaliplatin. These results were con-
firmed at 4- and 6-years [3, 4]. For stage II CC (T3-4/N0/
M0), the benefit of adjuvant chemotherapy remains con-
troversial and there is a significant heterogeneity in pa-
tients outcome within this stage. In the MOSAIC study,
high risk stage II patients defined as N0/M0 patients with
a T4 primary tumor, bowel obstruction, tumor perforation,
poorly differentiated tumor, tumors with satellite venous
or lymphatic invasion, or less than 10 lymph nodes exam-
ined, a non-significant gain of 3 % in disease-free survival
at 3-years was observed for the FOLFOX-4 arm compared
with the LV5FU2 arm (HR: 0.72 [0.48-1.08]) [5]. The pub-
lished QUASAR 2 study [6] compared adjuvant 5-FU plus
Folinic Acid ± Levamisole with no adjuvant chemotherapy
in 3,239 patients with colorectal cancer (92 % stage II in a
mixed population of 71 % colon and 29 % rectal cancer).
The results showed an absolute gain of 2.9 % in overall
survival at 5-years for the chemotherapy group for the
entire population (p = 0.02, and for stage II, p = 0.04). The
absolute benefit of adjuvant chemotherapy in stage II CC
patients is generally considered between 2 and 5 %. There-
fore, it is currently recommended that adjuvant therapy
shall be discussed on a case-by-case basis, considering the
risk-benefit ratio for each patient resected from a stage II
disease, with strong consideration given to patients with
high risk stage II CC as defined previously [7, 8].
The 20 to 30 % risk of local or distant recurrence ob-
served in patients with stage II/III, non-metastatic CC
operated in a curative intent and receiving adjuvant
chemotherapy reflects the relative failure of such a strat-
egy to prevent the risk of locoregional spread of tumor
cells or eradicate distant micrometastases. Several rea-
sons may explain this failure: the delayed start (up to
4 months) of chemotherapy after the initial diagnosis
and the rapid doubling time of colorectal metastases,
which may progress during this time interval without
chemotherapy [9]. The stimulation of growth factors
related to the operation and the immunosuppression
induced during the immediate postoperative period are
two other factors that may promote the growth of
micrometastases and tumor progression in the postop-
erative setting [10–12]. The initiation of a neoadjuvant
chemotherapy in these patients could improve progno-
sis by controlling these potential deleterious factors
and improving the completeness and the quality of the
cancer surgery by local "down-staging,” and by eradicating
circulating micrometastases. Neoadjuvant chemotherapy
could also test the response of the tumor and thus its
chemo-sensitivity; and when appropriate, adjuvant chemo-
therapy may be adapted.
The potential benefit of such a peri-operative strategy
in stage II/III CC is strengthened by: i) recent advances
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in radiology, which allows a good prediction of tumor
stage (wall penetration and nodal involvement) prior to
surgery [13, 14]; ii) the histological response observed in
primary colon tumors treated by systemic chemotherapy
[15] and iii) the demonstrated benefit of combining pre-
and postoperative chemotherapy and/or radiotherapy in
various gastrointestinal tumors (oesophageal, gastric,




The Prodige 22 - ECKINOXE trial is a multicenter ran-
domized phase II trial designed to evaluate efficacy (re-
sponse rate) and feasibility (safety, tolerability) of two
chemotherapy regimens (FOLFOX-4 alone and
FOLFOX-4 + Cetuximab) in a peri-operative setting in
patients with stage II/III CC. Control arm includes pa-
tients for whom standard treatment comprises surgery
followed by adjuvant FOLFOX-4 chemotherapy. This
phase II study will assess the feasibility of a peri-
operative strategy in these patients and the impact of
adding cetuximab in this setting for patients with RAS
wild type tumors.
A double central, independent and blinded review of
imaging and pathology is planned. All eligible patients
will be randomized to either surgery alone or neoadju-
vant chemotherapy with simplified FOLFOX-4. Patients
randomized to the simplified FOLFOX-4 arm will be
randomized to receive Cetuximab or not if they are RAS
WT
Thus based on the RAS status of the primary tumor the
design will be: Arm A vs. Arm B vs. Arm C for RAS WT
patients and Arm A vs. Arm C for those RAS mutated
(Fig. 1)
Arm A: simplified FOLFOX-4 alone every 2 weeks for
4 cycles, followed by colectomy, followed by simplified
FOLFOX-4 alone every 2 weeks for 8 cycles.
Arm B: Cetuximab plus simplified FOLFOX-4 every
2 weeks for 4 cycles, followed by colectomy, followed by
Cetuximab plus simplified FOLFOX-4 every 2 weeks for
8 cycles.
Arm C (control arm): Colectomy followed by simpli-
fied FOLFOX-4 alone every 2 weeks for 12 cycles. Adju-
vant chemotherapy will be given to all patients with
Fig. 1 Protocol overview. Temporal sequence of trial conduct in patients with RAS WT colon tumor (1A) or RAS mutated colon tumor (1B)
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stage III CC and according to the local practices for
stage II cancer.
Inclusion criteria
For inclusion in the study, all of the following inclusion
criteria must be fulfilled: (i) pathologically confirmed
colon adenocarcinoma (≥15 cm from the anal verge); (ii)
assessment of RAS status of the primary colon cancer on
biopsies (WT or mutated); (iii) CC classified by abdom-
inal CT scan: high risk T3 (disruption of muscle wall
and extension into pericolic fat with more than 5 mm
protrusion into adjacent mesenteric fat) - T4 (penetra-
tion within adjacent organs) and/ or N2 (more than 3
clustered lymph nodes above 1 cm in shortest diameter);
(iv) non metastatic CC (lung, liver, peritoneal); (v) non
complicated primary tumor (obstruction, perforation,
bleeding). Patients with obstructive CC and treated by
defunctioning stoma can be included; (vi) absence of
synchronous colorectal cancer ; (vii) age ≥ 18 years et ≤
75 years; (viii) ECOG performance status 0–1 ; (ix) no
prior chemotherapy or abdominal or pelvic irradiation;
(x) life expectancy of ≥ 5 years; (xi) no history of colorec-
tal cancer; (xii) patients with childbearing potential
should use effective contraception during the study and
the following 6 months; (xiii) laboratory data including :
white blood cell count ≥ 3 × 109/L with neutrophils ≥ 1.5 ×
109/L, platelet count ≥ 100 × 109/L, hemoglobin ≥ 9 g/dL
(5,6 mmol/l), total bilirubin ≤ 1.5 × ULN (upper limit of
normal), ASAT and ALAT ≤2.5 × ULN, Alkaline phos-
phatase ≤1.5 × ULN, serum creatinine ≤ 1.5 × ULN; (xiv)
signed written informed consent obtained prior to any
study specific screening procedures.
Exclusion criteria
Patients are not eligible for this study if any of the following
exclusion criteria apply: (i) contra-indication to iodinated
contrast medium injection including allergy to iodinated
contrast medium and renal insufficiency proscribing iodin-
ated injection; (ii) rectal cancer located within 15 cm from
the anal verge by endoscopy or under the peritoneal reflec-
tion at surgery or having received radiation therapy prior to
surgery; (iii) complicated primary CC (obstruction, bleed-
ing, perforation); (iv) synchronous colorectal cancer; (v)
metastatic spread at baseline assessment (lung, liver, peri-
toneal); (vi) history or current evidence on physical examin-
ation of central nervous system disease or; (vii) peripheral
neuropathy ≥ grade 1 Common Toxicity Criteria for Ad-
verse Events (CTCAE) v.3.0; (viii) known hypersensitivity
reaction to any of the components of study treatments; (ix)
presence of inflammatory bowel disease; (x) HNPCC syn-
drome or polyposis; (xi) major surgical procedure, open bi-
opsy or significant traumatic injury within 28 days prior to
study treatment start. Incompletely healed wounds or an-
ticipation of the need for major surgical procedure during
the course of the study; (xii) clinically relevant coronary ar-
tery disease or history of myocardial infarction in the last
12 months, or high risk of uncontrolled arrhythmia; (xiiii)
pregnancy (absence to be confirmed by ß-hCG test) or
breast-feeding period; (xiv) previous malignancy in the last
5 years; (xv) medical, geographical, sociological, psycho-
logical or legal conditions that would not permit the patient
to complete the study or sign informed consent; (xvi) any
significant disease which, in the investigator’s opinion,
would exclude the patient from the study.
Endpoints
By evaluating two chemotherapy regimens in patients with
RAS WT tumor (FOLFOX-4 vs. FOLFOX-4 – Cetuximab),
the present trial will determine which neoadjuvant regimen
is the most efficient in terms of response rate in patients
with non metastatic locally advanced CC.
The primary objective is to assess the histopathological
response to neoadjuvant chemotherapy measured by the
Tumor Regression Grade (TRG), as simplified to three
categories by Ryan [19]. The TRG-Ryan is based on the
relationship between fibrosis and the amount of residual
tumor cells is defined as follows (Fig. 2). The histopatho-
logical finding of fibrous stroma containing few viable
tumor cells can be naturally present in almost 10 % of
CCs not treated with chemotherapy prior to surgery
[15]. Therefore, this parameter represents an objective
measure of evaluation in the control (no pre-operative
chemotherapy) and study (neoadjuvant chemotherapy)
arms. This limits the risk of wrongly concluding therapy
efficacy, thereby meeting the methodological standards
of a Phase II randomized study. The histopathological
response to neoadjuvant chemotherapy will be centrally
assessed by 2 of the 3 members of our Central Review
Committee of Pathologists who will be blinded to the pa-
tients’ treatment. The objective of the blinded comparison
of TRG by two independent pathologists is to assess: (i)
the inter-observer reproducibility of this grading system in
CC after neoadjuvant chemotherapy; (ii) the specificity of
histological "regression" criteria by comparing, without
knowing the treatment arms, the histological features of
tumors operated on immediately versus that of tumors
treated by neoadjuvant chemotherapy.
Secondary endpoints are the following: (i) postopera-
tive morbidity (occurring within 60 postoperative days)
graded 0 to 5 according to the Clavien-Dindo classifica-
tion [20]. If grade 3 or 4 complications occur at a rate ≥
10 % in either neoadjuvant chemotherapy arm, the arm
will be declared hazardous (see section statistical ana-
lysis); (ii) the safety of neoadjuvant therapy will be
assessed by the systematic collection of toxicity data
related to chemotherapy, the total number of cycles
administered pre-operatively (documenting reasons for
early termination), and the systematic collection of GI
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symptoms. In addition, complications related to the in situ
tumor that could delay the date of surgery or require emer-
gency colonic surgery or stenting, will be documented.
These parameters will be evaluated after administration of
the first cycle of neoadjuvant chemotherapy; (iii)
Regression-free survival at 3-years defined as the time inter-
val between the date of randomization and the date of first
recurrence (local, regional or metastatic) or date of death
(all causes) if no recurrence; (iv) Disease-free survival at
3 years defined as the time interval between the date of
randomization and the date of first recurrence (local, re-
gional or metastatic), or second cancer, or the date of death
without recurrence (all causes) and date of second cancer;
(iv) Quality of life (evaluated using the EORTC quality of
life (QoL) QLQ-C30 and QLQ-CR29); Quality of life will
be assessed at the inclusion, after neoadjuvant chemother-
apy, at 1 month after surgery and every 6 months there-
after. The QLQ-C30 consists of 30 items with both multi-
items scales and single item measures. The internal valid-
ation of QLQ-C30 allowed to identify 15 scales and to gen-
erate 15 scores: 5 scores of functional scale (physical
functioning, role functioning, cognitive functioning, emo-
tional functioning, social functioning), a global health status
scare, a financial difficulties scale and 8 symptoms scale (fa-
tigue, nausea/ vomiting, pain, dyspnoea, insomnia, appetite
loss, constipation, diarrhoea). These scores vary from 0
(worse) to 100 (better) for functional and global health scale
and from 0 (better) to 100 (worse) for symptoms scales.
Targeted QoL dimensions for this trial are Global Health,
physical and emotional functioning, fatigue and pain of
QLQ-30 as well as dimensions of CR29. A 5 points differ-
ence in QoL is considered as minimal clinically important
difference (MCID). Time to QoL deterioration will be de-
fined as time interval between randomization and first de-
crease in QoL score greater or equal to 5 points. Patients
without QoL decrease greater or equal to 5 points will be
censored at the last follow-up. (v) Quality and completeness
of the surgical excision evaluated on pathological criteria
(number of lymph nodes examined, the completeness of re-
moved mesocolon, surgical margins); (vi) radiological sta-
ging and radiological response. The initial radiological
staging based on abdominopelvic CT scan will be compared
with the histopathological pTNM staging in the control
group. CT scan images will be interpreted by the individual
study centers, and reviewed by 2 of the 3 members of our
Central Review Committee of Radiology. This dual inde-
pendent reading will assess inter-observer reproducibility of
the radiological response to treatment with a test of con-
cordance. The radiological response will be defined by
RECIST (v1.1) [21] on CT scan and evaluated in the neoad-
juvant chemotherapy arms. These criteria will be applied to
the primary colon tumors (largest diameter) and lymph
nodes (smallest diameter). The sum of the diameters of the
target lesions will be determined on the pretreatment CT
scan (initial staging) and compared with the sum of these
measures on the reevaluation CT scan (performed within
3 weeks after the completion of neoadjuvant chemother-
apy). Interpretation of the reevaluation CT scan will be cen-
tralized and carried out independently by 2 of the 3
members of our Central Review Committee of Radiologists
blinded to the pretreatment CT scan staging. This dual in-
dependent reading will assess inter-observer reproducibility
of RECIST criteria applied to CC, and determine if there is
a difference in radiological response between the two
chemotherapy regimens under investigation in the study;
(vii) Correlation between histopathological and radiological
response. The radiological response of the primary tumor
as defined by RECIST v1.1 criteria (taken for target lesion,
only the primary tumor) will be compared with the histo-
pathological response as defined by TRG-Ryan. Evaluation
of this correlation will be centralized and carried out by the




Fig. 2 The Tumor Regression Grade (TRG), as simplified to three categories by Ryan (19). TRG1: Major response; TRG2: Intermediate response;
TRG3: No response
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(viii) The 5-point regression grading system [22] adapted to
CC by our team in a pilot study [15], will also be evaluated
in this trial. This assessment will be centralized and car-
ried out independently and blindly (without knowing
the treatment arms) by 2 of the 3 members of our Cen-
tral Review Committee of Pathology. This assessment
will determine the inter-observer reproducibility of this
grading system in CC after chemotherapy and to assess
the specificity of histological "regression" criteria using
this grading system. Comparison of the reproducibility
(test of concordance) of the two systems of grading re-
gression (TRG-Ryan and TRG-Mandard) will identify
the most appropriate system for assessing response to
chemotherapy in CC.
Randomisation
After completion of all the screening evaluations (all the in-
clusion criteria satisfied and none of the exclusion criteria
apply) and signature of the informed consent(s), all eligible
patients will be randomly assigned by the randomisation
center of the French Federation of Digestive Oncology
(FFCD) to one of the treatment arms according to the RAS
status: RAS WT patients will be randomised between 3
treatment arms (Arm A vs. Arm B vs. Arm C) and those
mutated for RAS between 2 treatement arms (Arm A vs.
Arm C). The randomization will be stratified according to
the investigator center, T stage (T1/2/3 vs. T4) of the pri-
mary tumor on the pretreatment CT scan and N stage (N0-
N1 vs. N2) of the primary tumor on the pretreatment CT
scan. The screening/baseline assessment will take place
within the 3 weeks prior to randomization, randomization
will be done between 4 and 8 weeks after surgery and the
maximum time between randomization and treatment start
will be 15 days.
Pre-therapeutic work-up
The screening visit must be performed within 3 weeks be-
fore the randomisation. During this visit, inclusion and ex-
clusion criteria are checked and validated. The complete
pre-therapeutic work-up includes a physical examination,
standard laboratory tests with CEA level, complete colonos-
copy with biopsies and a CT scan of the thorax, abdomen
and pelvis. Clinical tumoural staging (cTNM) will be based
on the data obtained from CT scan. The determination of
the RAS status (KRAS and NRAS mutations located within
the exons 2, 3 and 4) of the primary tumor will be per-
formed from biopsies obtained during the diagnostic colon-
oscopy, by each centers at the “plateformes de génétique
somatique des tumours” labelled by the National Institut of
Cancer (INCa). Once baseline assessments are completed,
check and validation of inclusion and exclusion criteria for
the study will be performed at the oncological multidiscip-
linary meeting of each center.
Treatment methods
The treatment protocols are standardized with regard to
radiological and pathological parameters, based on the rec-
ommendations of I’INCa, the FFCD, the French Society of
Pathology, the French Society of Digestive Endoscopy and
the French Society of Digestive Surgery. Treatment applica-
tion depends on the RAS status of the primary tumor
(Fig. 1) and must start within 14 days after the
randomisation.
Neoadjuvant chemotherapy requires an implantable sub-
cutaneous venous access and will be administrated for 4 cy-
cles. The following assessments will be performed prior to
each cycle (every two weeks) before chemotherapy adminis-
tration: documentation of concomitant medication and
concurrent procedures; physical examination; vital signs
and ECOG performance status; blood sampling for
hematology and clinical biochemistry and recording of
adverse events since last cycle (including primary tumor re-
lated symptoms or complications). The end of treatment
visit must be performed 15 days after the 4th cycle
administration.
FOLFOX-4 chemotherapy
The simplified FOLFOX-4 (Oxaliplatine, ELOXATINER
(85 mg/m2), with simplified LV5FU2) is administrated
intravenously over 48 hours once every two weeks (i.e. on
d1/d2, d15/d16, d29/d30 etc.). The FOLFOX-4 regimen
will be administrated as follows: Oxaliplatin will be admin-
istered as an 85 mg/m2 intravenous infusion over 2 hours
(on day 1 only) concomitantly with LV, as a 400 mg/m2
infusion over 2 hours, followed by 5- fluorouracil (5-FU),
given as a 400 mg/m2 bolus injection (over 10 minutes),
and then as a 2400 mg/m2 continuous infusion over
46 hours. Cycle length is 2 weeks comprising 48 hours of
infusion and 12 days of rest. These cycles must be re-
peated every second week. A total of 12 cycles (4 cycles
preoperatively, 8 cycles postoperatively) will be adminis-
trated to all patients in Arm A and B. In Arm C (control
Arm), only patients with stage III CC (on pathological
examination) will receive 12 cycles of adjuvant chemother-
apy. For those with stage II CC, the decision of adjuvant
chemotherapy in this Arm will be will be done according
to the investigator discretion.
FOLFOX-4 + Cetuximab chemotherapy
Patients in Arm B only will receive Cetuximab according
the same schedule of the FOLFOX chemotherapy, i.e. once
every two weeks (on d1, d14, d28, etc.…). Cetuximab will
always be administered first, i.e. the Cetuximab infusion
should be completed one hour before chemotherapy be-
gins. The Cetuximab dose must always be based on the
body surface area (BSA). There is no restriction for
Cetuximab in patient with a BSA > 2.0 m2. The dosage and
administration procedure for Cetuximab is as follows:
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- The first infusion is 500 mg/m2. As prophylaxis to
reduce the risk of an allergic/hypersensitivity reaction, it
is mandatory to pretreat the patient as specified below.
Cetuximab is administered as follows: the volume is ad-
ministered over 120 minutes (maximum rate of 5 mL/
min). Saline solution (0.9 %) is used to flush the line at
the end of the infusion. Vital signs are checked before,
during, immediately after and 1 hour after the end of the
infusion.
The subsequent weekly doses are 500 mg/m2. Cetuximab
is administered as follows: the volume is administered over
60 minutes (maximum rate of 10 mL/min). Saline solution
(0.9 %) is used to flush the line at the end of the infusion.
Surgery will be performed 3 to 5 weeks after the last
cycle of neoadjuvant chemotherapy (in arms A and B) or
within 14 days after the randomisation. The anesthetic
evaluation, patient’s information regarding the operative
procedure and the organization of the hospitalization
will be performed according to the local practices of
each investigator center. The colectomy will be per-
formed by laparotomy or laparoscopy (investigator dis-
cretion) with respect of the oncological quality criteria
of resection. Per and postoperative data will be collected
and reported in specific forms.
Adjuvant chemotherapy will be administrated for all
patients included in arms A (FOLFOX-4) and B
(FOLFOX-4 +Cetuximab). Eight additional cycles will be
administrated (for a total of 12 cycles) according the
same regimen. In Arm C (control Arm), only patients
with stage III CC (on pathological examination) will re-
ceive 12 cycles of adjuvant chemotherapy. For those with
stage II CC, the decision of adjuvant chemotherapy in
this arm will be will be done according to the investiga-
tor's discretion.
Data collection and follow-up
For all patients, follow-up assessment will be performed
until recurrence and/or death. For the study, the recur-
rence free survival will be assessed at 3 years. For patients
included in the present trial, the follow-up will be system-
atic and performed thereafter this period according to the
good clinical practices. The follow-up schedule and inves-
tigations proposed for the present study are those recom-
mended by the FFCD [8].
Every 6 months, the following investigations will be per-
formed: tumor assessment, CEA measurement, survival sta-
tus, additional cancer therapy. Moreover, the following
assessments will be performed during the follow-up:
colonoscopy 3 years after surgery then every 3 to 6 years,
assessment of neurological toxicity, and assessment of elec-
trolytes (magnesium, calcium, potassium) at the second fol-
low up visit (12 months after surgery) if still abnormally
decreased at end of treatment assessment.
Statistical analysis and sample size
Patients RAS Wild Type will be randomized between
arm A, B and C whereas RAS mutated patients will be
only randomized between arm A and arm C. According
to Simon (Optimax) 2 steps design, it will be required to
include 33 patients/ arm (with unilateral alpha type one
error of 5 % and a power of 95 %) to test following
hypotheses: (i) H0: an histological response (TRG1-Ryan)
rate of 10 % is uninteresting; (ii) H1: an histological
response (TRG1-Ryan) higher than 10 % is required to
rate pursue investigations in phase III trial. A response
rate of 35 % is expected.
At the first step (interim analysis), after inclusion of
the first 13 patients in each arm, if the number of histo-
logical response (TRG1-Ryan) is ≤ 1, inclusion in this
arm will be stopped and if the number of histological
response (TRG1-Ryan) is ≥ 2, inclusion of the next 20
patients will be done. Calculated power at the interim
analysis is 97 %.
At the 2nd step (final analysis), after inclusion of 33
patients in each arm, if the number of histological response
(TRG1-Ryan) is ≤ 6, this arm will be declared uninteresting
for further investigations in phase III trial and if the number
of histological response (TRG1-Ryan) is ≥ 7, this arm will
be declared interesting for further investigations in phase
III trial. At the second step calculated power will be 96.3 %
and alpha type one error will be 2 %. In control arm no in-
terim analysis is plan for efficacy. Then in this arm, at the
second step, calculated power will be 97.2 % and alpha type
one error will be 4.2 %. If ≥ 10 % of complications ≥ grade
III (Clavien and Dindo classification) within 60 postopera-
tive days are reported, this arm will be declared unsafe.
Interim and final results of this phase II study will be
reviewed by an independent data monitoring committee
(IDMC). Trial will be pursued in phase III with 2 or 3
arms according to IDMC recommendations. Control
arm (no neoadjuvant treatment) will be kept as control
arm in phase III whatever the results of phase II study.
Required number of patients is 33 × 3 = 99 patients for
RAS WT patients and 33 × 2 = 66 for those with RAS
mutated. Taking into account prevalence of RAS WT
patients of 50 %, it will be necessary to screen 192 pa-
tients to obtain 99 patients RAS WT and 66 patients
mutated for RAS with a minimal probability of 90 %.
Participating centres
Fifty seven French centres will participate in the study:
Amiens University Hospital, Caluire et Cuire Hospital in
Lyon, University Hospital of Clermont-Ferrand, General
Hospital Center of Orléans, European Georges Pompidou
University Hospital in Paris, Claude Huriez University
Hospital in Lille, North University hospital of Bordeaux,
University Hospital of Nîmes, Purpan University Hospital
in Toulouse, Paoli Calmettes Cancer Institute in Marseille,
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Henri Mondor University Hospital in Créteil, North
University Hospital in Marseille, Saint-Louis University
Hospital in Paris, Pitié Salpêtrière University Hospital in
Paris, Ambroise Paré University Hospital in Boulogne-
Billancourt, St André University Hospital in Bordeaux,
General Hospital Center in Beauvais, Croix-Rousse Uni-
versity Hospital in Lyon, Beaujon University hospital in
clichy, Pessac University Hospital of Bordeaux, the Univer-
sity Hospital in Strasbourg, Pontchaillou University
Hospital in Rennes, General hospital in Bézier, Robert
Debré University Hospital in Reims, Avicenne University
Hospital in Bobigny, Cochin University Hospital in Paris,
St Anne Clinic in Strasbourg, University Hospital of
Nantes, Jean Mermoz Private Hospital in Lyon, University
Hospital in Grenoble, La Timone University Hospital in
Marseille, Saint Antoine University Hospital in Paris,
General Hospital of Pau, Paul Strauss Cancer Institute in
Strasbourg, University Hospital of Dijon, Saint Joseph
Private Hospital in Paris, University Hospital of Rouen,
Rangueil University Hospital in Toulouse, Sainte Barbe
Clinic in Strasbourg, Sainte Catherine Institut in Avignon,
The Asclepios House Clinic in Avignon, General Hospital
of Bayonne, Eugene Marquis Cancer Institut of Rennes,
Intercommunal Hospital Center of Creteil, General
Hospital of Mont de Marsan, Bichat University Hospital in
Paris, Grand Sud Polyclinic of Nîmes, Kenval Polyclinic of
Nîmes, Valdegour Clinic Oncogard Center of Nîmes, Gen-
eral Hospital of Boulogne Sur Mer, University Hospital of
Poitiers, University Hospital of Brest, Saint Joseph-Saint
Luc Hospital in Lyon, Synergia Polyclinic in Carpentras,
General Hospital of Avignon, University Hospital of Saint
Etienne.
Ethics and safety
This study protocol was approved by the Institutional Re-
view Board, the Ile de France IX ethic committee on No-
vember 2011 and the AFSSAPS (Agence Française de
Sécurité Sanitaire des Produits de Santé) on September
2011 under the registration number A110936-41. The insti-
tutional promoter is the Assistance Publique Hôpitaux de
Paris, France. The trial has been registered on Clinical-
Trial.gov website under the identification number
NCT01675999. This study received a grant from the
French National Cancer Institute (INCA) in 2010. The
study complies with the Declaration of Helsinki rules and
the principles of the Good Clinical Practices guidelines. In-
formed consent will be obtained from each patient in a
written form prior to randomisation. Patient safety and all
potential threats to the patients will be monitored every
6 months by an independent data safety monitoring board
(DSMB) and, additionally, at the discretion of the DSMB or
Promoter. The DSMB also will evaluate the primary end-
point data. Qualified personnel at the sponsor site will also
meet every three months to review safety data, including
adverse events and serious adverse events. Any information
deemed to potentially affect the safety of the trial will be
brought to the attention of the DSMB. An Independent
committee (IDMC) including at least 1 clinicien, 1 method-
ologist and pharmacologist will be created before trial initi-
ation. This IDMC should statute on efficacy and safety at
the interim analysis regarding decision criteria of Simon de-
sign, post operative morbidity.
Discussion
There are several arguments in favor of performing a
study to assess the impact on survival of perioperative
chemotherapy in the treatment of stage II/III CC.
Three prerequisites are however essential. First, sys-
temic chemotherapy must be effective and able to in-
duce a measurable and reproducible response of the
primary tumor. Second, current preoperative imaging
with abdominopelvic CT scan must allow for an accur-
ate assessment of tumor stage to justify antineoplastic
treatment with a limited number of false-positives pa-
tients in order not to over-treat patients that do not re-
quire such treatments. Finally, the neoadjuvant
chemotherapy must be well tolerated and not increase
the risk of pre- and post-operative complications.
Tumor Histopathological response to chemotherapy
The histopathological changes induced by neoadjuvant
chemotherapy and/or radiotherapy have been studied in
several digestive cancers, such as cancer of the esophagus,
stomach, rectum and liver metastases of colorectal origin
[19, 23–27]. In these cancers, histopathological changes in-
cluded increased fibrosis, the appearance of acellular necro-
sis, inflammatory infiltration, the appearance of colloid
pools and the reduction or disappearance of tumor cells.
However, no grading system for histopathological response
has been validated to date [22, 27, 28]. In CC, the "local"
effect of systemic chemotherapy on the primary tumor
has long been suspected based on indirect arguments
from patients receiving chemotherapy for metastatic
disease without resection of the primary tumor, such as
resolution of clinical symptoms and radiological
changes. In a pilot study [15], we characterized the
histopathological changes and assessed the response of
primary colon tumors among patients with metastatic
CC treated with chemotherapy first and subsequently
resected. The grading system for the histopathological
tumor regression was based on that of Mandard and
collaborators [22], derived from the study of tumor re-
sponse after chemoradiation in squamous cell cancer of
the esophagus, then adapted by Rubbia-Brandt and col-
leagues [27] for the regression of liver metastases of colo-
rectal origin. In our study, when compared with a control
group, neoadjuvant chemotherapy was associated with ex-
tensive fibrosis and marked lymphoplasmacytic infiltration
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in nearly half the cases, and changes in the mucosa overly-
ing the tumor (normal colonic mucosa or inflammatory ul-
ceration) in 75 % of cases. Using the Tumor Regression
Grade (TRG), nearly 70 % of CCs treated with neoadjuvant
chemotherapy showed signs of major histological response
characterized by fibrosis outgrowing residual cancer cells.
The histological response in the primary tumor was corre-
lated to that observed in liver metastases for 9 patients op-
erated on for both colon and liver metastases after
chemotherapy [15].
Selection of patients with locally advanced CC by CT scan
Hundt and colleagues reported on the sensitivity of
helical CT in imaging colorectal cancer in 37 patients
[29]. Arterial and portal phases were examined. The
overall sensitivity for detecting cancer was 97 % in both
phases, and 86 % in the portal phase alone. The sensitiv-
ity for the detection of lymph node involvement when
correlated with pathological data was 67.6 %, with 23
node positive patients detected out of a total of 34. The
positive predictive value of CT (1 lymph node greater
than 1 cm, or more than 3 lymph nodes less than 1 cm
in diameter with a maximum enhancement greater than
100 HU) was 95.4 %. The overall accuracy of CT com-
pared with pathologic stage was 81 %. Of the 18 T1 or
T2 tumors, only two were incorrectly classified as T3
based on the scans. For the 19 T3 or T4 tumors, only
two were incorrectly classified as T2.
More recently, Burton and colleagues sought to inves-
tigate if the CT scan could elucidate poor prognostic fac-
tors for CC in order to select a subset of patients eligible
for neoadjuvant treatment [30]. Three patients were im-
aged by a single shot spiral CT with a 10 mm collima-
tion and a pitch of 1. The portal phase was scanned,
after the upper gastrointestinal tract was opacified with
water. Returning to the criteria set forth in the literature
to distinguish T0-T2 from T3-T4 tumors, the authors
proposed that CT could highlight poor prognostic fac-
tors (extension to adjacent organs, extension greater
than 5 mm in to the peritoneal fat, lymph node involve-
ment) that correlated with pathological data. Of 14
tumors determined to be T3 on pathology, 10 (71.4 %)
were correctly classified as T3 by CT, one was incor-
rectly upstaged to T4 by CT (7.1 %), and 3 were incor-
rectly down-staged by CT (21 %). For the 12
pathologically determined T1 and T2 tumors, between 3
and 5 tumors were classified as T3 by CT. Finally, of the
seven T4 tumors, between one and two tumors were
classified as either T0 or T2 based on CT. Regarding
lymph node status, the presence of 1 to 3 positive nodes
greater than 1 cm, or the grouping of more than 3 posi-
tive nodes less than 3 mm in short axis, or the grouping
of more than 3 positive nodes more than 1 cm in short
axis (N2) provided an accuracy of 64 % for lymph node
staging. These results were comparable to those previ-
ously reported in other studies [31]. According to radiol-
ogists, there was an over-staging in 24 to 30 % of cases.
By exploiting the radiological data of this study, Smith
and colleagues [32] compared groups of patients with
and without poor prognostic factors by CT scan.
Disease-free survival at 3 years was 71 % in the group
with a good prognosis CT versus 43 % in the poor prog-
nosis CT group (p <0.0066). These results were similar
to those based on pathologic staging, with 75 % versus
43 % survival at 3 years. The authors concluded that CT
staging could differentiate between patients with good
and poor colorectal cancer prognosis. These data were
recently confirmed in a series of 94 patients recruited
from 18 centers [14].
The choice of neoadjuvant chemotherapy regimens
FOLFOX-4 is the standard of care treatment given postop-
eratively for 6 months in patients with stage III CC [4]. In
advanced disease, the effectiveness of FOLFOX-4 has been
demonstrated in terms of response rate, progression-free
survival and overall survival, with good patient tolerability
[33–38]. In advanced disease with resectable liver metasta-
ses, the efficacy of perioperative chemotherapy with
FOLFOX-4 (6 cycles before and 6 cycles after surgery) was
demonstrated in a prospective, randomized trial [18]. In
this study of 364 patients with 1 to 4 resectable liver metas-
tases, a 9.2 % benefit in progression-free survival at 3 years
was observed in the treatment arm (33.2 % [25.3-41.2] vs.
42.4 % [34.0-50.5], HR 0.73 [0.55-0.97], p = 0.025) at the
cost of increased postoperative morbidity (25 % vs. 15.9 %,
p = 0.04) and more biliary complications. In this study, 37
of 171 patients (39 %) treated with neoadjuvant FOLFOX-4
had a partial or complete radiographic response by RECIST
criteria.
The combination of FOLFOX-4 and Cetuximab has
also been demonstrated to be effective with regard to re-
sponse rate (57 to 81 %) and progression-free survival
with good tolerance, in patients with non-mutated KRAS
(wild-type) metastatic colorectal cancer [39–46]. Two
Phase III trials comparing FOLFOX-4 and FOLFOX-4
plus Cetuximab after resection of stage III CC have
demonstrated no benefit when adding cetuximab. In the
US NCCTG NO147 trial, the three-year disease-free sur-
vival for mFOLFOX6 alone was 74.6 % vs. 71.5 % with
the addition of cetuximab (HR, 1.21; 95 % CI, 0.98-1.49;
P = .08) in 1863 patients with wild-type KRAS. In the
European PETACC8 trial including 2564 patients, the 3-
year disease-free survival in the 1602 KRAS WT patients
was 78 % in the FOLFOX arm and 75 % in the cetuximab
arm (p = 0.652). However though both trials are negatives,
and didn’t show any benefit of adding cetuximab to FOL-
FOX in term of DFS for resected stage III CC, no detri-
mental effect of the FOLFOX+ cetuximab combination
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therapy was observed even in patients with KRAS mutated
tumors. The use of this combination therapy in the neoad-
juvant setting, in RAS WT patients, remains to our opin-
ion an attractive option for two reasons: the high reported
response rates observed with this schedule in metastatic
patients (57 to 81 %) with a manageable toxicity profile
and the significant increase in disease-free survival when
adding cetuximab in the subgroup of patients operated
from a locally advanced (pT4N2) tumor reported in the
PETACC8 trial.
The aim of our phase II ECKINOXE study is to
evaluate the efficacy (response rate) and tolerability of
two regimens of neoadjuvant chemotherapy among pa-
tients with locally advanced CC. The control arm will
consist of patients treated with FOLFOX-4 post-
operatively. This study will allow us to investigate the
feasibility and effectiveness of this original neo-
adjuvant strategy, and to select the best regimen to im-
prove long-term disease-free and overall survivals. A
similar study testing another anti-EGFR monoclonal
antibody (Panitumumab) is currently ongoing in the
United Kingdom (FOxTROT trial). The pilot stage of
this randomised controlled trial on the first 150 in-
cluded has been recently published. Nearly 90 % (85 of
95) of patients in this trial completed preoperative
chemotherapy with grade 3–4 gastrointestinal toxicity
in 7 %. All 99 tumours in the preoperative group were
resected, with no significant differences in postopera-
tive morbidity between the preoperative and control
groups. T3 or more advanced tumours was pathologic-
ally confirmed in 98 % of patients undergoing immedi-
ate surgery and 91 % of patients following preoperative
chemotherapy (p = 0 · 10). Preoperative therapy re-
sulted in significant downstaging in terms of TNM
stage compared with the postoperative group (p = 0 ·
04), including two pathological complete responses.
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